Charles River Laboratories International, Inc. CRL
Composite 40/100; the shares have moved about 50% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 17/100 — a strong mark against it.
Momentum ranks 86/100 — a strong point in its favour.
Growth ranks 17/100 — a strong mark against it. Quality ranks 27/100 — a moderate mark against it. Valuation ranks 34/100 — a moderate mark against it.
What the company does Charles River Laboratories provides drug discovery, non-clinical development, and safety testing services globally. Its segments include Research Models and Services (rodents and related services), Discovery and Safety Assessment (preclinical drug testing), and Manufacturing Solutions (cell therapy and biologic production).
Key financials Revenue declined -0.9% while EPS fell -685.5%. Margins show gross 34.6%, operating 15.1%, and net -6.0%. ROE is -7.5%, ROA 4.1%, and ROCE -1.2%. Debt/Equity stands at 1.05 with net debt/EBITDA at 3.35 and interest coverage at -0.73.
Stock health Sideravia scores the stock Poor quality (26.9 Quality, 19.0 Growth) but with strong Momentum (88.4). The Piotroski F-Score is 5/9 and Altman Z is 2.60. RSI(14) is 76.30, indicating overbought conditions.
Price vs fair value The stock trades at a PREMIUM of 4.80% versus the analyst mean target of 281.00. - Recent push into vaccine development highlighted as a growth driver (Simply Wall St.) - Stock rallied 33.3% in the past month, prompting questions about sustainability (Zacks) - Options activity suggests expectations of a significant move (Zacks) - Year-over-year gain of 88.6% cited as momentum-driven (Zacks) - Insider CEO focus on strategic reassessment noted (The Wall Street Journal)
Looking forward Forward P/E is 25.13 with EV/EBITDA at 73.32. The company’s expansion into high-growth areas like vaccines and cell therapies may support long-term revenue, but current margins and profitability remain weak. Momentum indicators suggest near-term caution despite strong recent performance.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.